Halozyme Therapeutics (NASDAQ:HALO) Trading Down 8.7% After Earnings Miss

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares dropped 8.7% during mid-day trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $73.00 and last traded at $73.4740. Approximately 2,311,550 shares were traded during trading, an increase of 17% from the average daily volume of 1,975,592 shares. The stock had previously closed at $80.48.

The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. During the same quarter last year, the business posted $1.26 earnings per share. The company’s revenue for the quarter was up 51.6% on a year-over-year basis.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record full‑year revenue and strong forward guidance — Halozyme reported 2025 total revenue of $1.397B (up 38% YoY) and reiterated 2026 guidance calling for $1.71–$1.81B in revenue, a sharply higher adjusted EBITDA range and $7.75–$8.25 non‑GAAP EPS guidance, which supports longer‑term revenue growth expectations. HALO FY2025 Results & Guidance
• Positive Sentiment: Royalty momentum and strategic technology acquisitions — Royalty revenue reached a record ~$868M (up ~52% YoY) and Halozyme completed acquisitions (Hypercon technologies) that management says will broaden product/enhancer applications, supporting recurring royalty upside. Royalty Growth & Acquisitions
• Neutral Sentiment: Q4 revenue beat but watch accounting/one‑offs — Q4 revenue of $451.8M modestly topped consensus, and slides/transcript provide detail that much of the story is royalty mix and GAAP items — investors should read the earnings deck/transcript to assess how much of the EPS swing is non‑recurring. Yahoo — Q4 Highlights
• Neutral Sentiment: Investor resources available — Management’s slide deck and full earnings transcript are posted (useful for modelling royalty cadence, margin drivers, and the components of the EPS miss). Earnings Presentation
• Negative Sentiment: Surprise quarterly loss / large EPS miss — Halozyme reported GAAP EPS of ($0.24) vs. consensus near $1.90+ (wide miss), with an operating loss and net loss driven by higher cost of sales and other items; that shock to EPS is the main catalyst for the selloff. Earnings Call Transcript
• Negative Sentiment: Wider operating loss, rising liabilities and cash dynamics — Q4 showed an operating loss and a notable rise in total liabilities; while cash increased modestly, investors are focused on margin pressure and how recurring royalty growth offsets cost trends. QuiverQuant Financial Highlights
• Negative Sentiment: Recent insider selling and mixed analyst positioning — Large insider sales disclosed in filings and a range of analyst price targets (median ~$84.5 but with some lower targets) add to near‑term uncertainty and pressure on the stock. Insider & Analyst Notes

Analyst Ratings Changes

Several equities analysts have recently issued reports on HALO shares. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, February 3rd. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Finally, Citizens Jmp lifted their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $77.44.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the sale, the chief executive officer owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. This represents a 2.74% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 49,398 shares of company stock worth $3,650,592. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. DLD Asset Management LP lifted its holdings in shares of Halozyme Therapeutics by 20.0% in the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after purchasing an additional 5,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after acquiring an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after acquiring an additional 25,731 shares in the last quarter. Norges Bank purchased a new position in Halozyme Therapeutics during the 4th quarter worth $128,201,000. Finally, William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth $124,031,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

The company’s 50 day moving average price is $71.55 and its 200-day moving average price is $70.25. The stock has a market cap of $8.63 billion, a P/E ratio of 15.50, a price-to-earnings-growth ratio of 0.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.